{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:49:54Z","timestamp":1776840594927,"version":"3.51.2"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clml.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T20:55:48Z","timestamp":1631307348000},"page":"e149-e160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed\/Refractory Lymphomas: A Single Center Experience"],"prefix":"10.1016","volume":"22","author":[{"given":"Asif Husain","family":"Osmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Khafaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-0944","authenticated-orcid":false,"given":"Saad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.003_bib0001","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0002","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2011.07.020","article-title":"Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation","volume":"18","author":"Kaloyannidis","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1634\/theoncologist.2011-0177","article-title":"Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma","volume":"17","author":"Colpo","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.003_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0006","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00277-018-3283-z","article-title":"Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant","volume":"97","author":"Elshenawy","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.09.003_bib0007","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ijrobp.2018.12.006","article-title":"A prospective, multicenter study of Involved- Field Radiation Therapy with autologous stem cell transplantation for patients with hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04\/TROG 03.03)","volume":"103","author":"Wirth","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.09.003_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clml.2017.09.011","article-title":"Consolidative radiotherapy after autologous stem cell transplantation for relapsed or refractory diffuse large b-cell lymphoma","volume":"18","author":"Coutu","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.09.003_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.09.003_bib0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","article-title":"Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lymphoma with incomplete response before autologous stem cell transplantation","volume":"17","author":"Levis","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.09.003_bib0011","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.09.003_bib0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1705239","article-title":"ESHAP\u00a0+\u00a0fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients","volume":"37","author":"Akhtar","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0013","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0014","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2021.09.003_bib0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clml.2020.08.028","article-title":"Favorable Outcome After Adjuvant Involved-Field Radiotherapy After Autologous Hematopoietic Stem-Cell Transplantation in Patients With High-Risk Relapsed\/Refractory Lymphoma: A Single-Center Experience","volume":"21","author":"Kaloyannidis","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.09.003_bib0016","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2011.12.031","article-title":"Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma","volume":"103","author":"Biswas","year":"2012","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clml.2021.09.003_bib0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.canrad.2019.02.002","article-title":"The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant","volume":"23","author":"Furlan","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.clml.2021.09.003_bib0018","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood MarrowTransplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0019","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.09.003_bib0020","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood-2018-99-112235","article-title":"Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"132","author":"Hagenbeek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.003_bib0021","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.09.003_bib0022","first-page":"2806","volume":"130","author":"Cassaday","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.09.003_bib0023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2019-123925","article-title":"Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study","volume":"134","author":"Stamatoullas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.003_bib0024","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.003_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"Lacasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.003_bib0026","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.003_bib0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.003_bib0028","first-page":"3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","author":"Armand","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.09.003_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.003_bib0031","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.003_bib0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0034","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0035","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0036","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin lymphoma: meta-analysis of the randomized trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0037","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved field radiotherapy before high dose therapy and autologous stem cell recue in Diffuse Large cell Lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.003_bib0038","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease","volume":"92","author":"Filippi","year":"2015","journal-title":"J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.09.003_bib0039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00066-020-01682-0","article-title":"Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma","volume":"197","author":"Pepper","year":"2001","journal-title":"Strahlentherap Onkol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:56Z","timestamp":1761871076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2152265021020322"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed\/Refractory Lymphomas: A Single Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}